bioAffinity Technologies Files 8-K on Corporate Changes
Ticker: BIAFW · Form: 8-K · Filed: Sep 17, 2025 · CIK: 1712762
Sentiment: neutral
Topics: corporate-governance, filing, disclosure
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K on 9/17/25 covering corporate changes and disclosures.
AI Summary
On September 17, 2025, bioAffinity Technologies, Inc. filed an 8-K report detailing material modifications to security holder rights, amendments to its articles of incorporation, and Regulation FD disclosures. The filing also includes financial statements and exhibits, indicating ongoing corporate actions and reporting requirements.
Why It Matters
This filing signals significant corporate governance updates and regulatory disclosures for bioAffinity Technologies, Inc., impacting security holders and potentially influencing investor perception.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain immediate negative financial or operational news.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- September 17, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41463 (company_id) — Commission File Number
- 46-5211056 (ein) — EIN
FAQ
What specific material modifications were made to the rights of security holders?
The filing indicates material modifications to the rights of security holders, but the specific details are not provided in the provided text snippet. Further review of the full filing is required.
Were there any amendments to bioAffinity Technologies' articles of incorporation or bylaws?
Yes, the filing explicitly lists 'Amendments to Articles of Incorporation or Bylaws' as an item of information, indicating such changes have occurred.
What is the significance of the Regulation FD Disclosure mentioned?
Regulation FD (Fair Disclosure) ensures that material non-public information is disclosed to all investors simultaneously, suggesting that the company is making a public disclosure of information that might otherwise be selectively shared.
What is the company's state of incorporation and fiscal year end?
bioAffinity Technologies, Inc. is incorporated in Delaware and its fiscal year ends on December 31st.
What are the company's primary business address and phone number?
The company's business address is 3300 NACOGDOCHES ROAD, SUITE 216, SAN ANTONIO, TX 78217, and its business phone number is 210-698-5334.
Filing Stats: 1,156 words · 5 min read · ~4 pages · Grade level 11.5 · Accepted 2025-09-17 16:30:40
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 52KB
- ex3-1.htm (EX-3.1) — 12KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 272KB
- 0001493152-25-013892.txt ( ) — 671KB
- biaf-20250917.xsd (EX-101.SCH) — 4KB
- biaf-20250917_def.xml (EX-101.DEF) — 26KB
- biaf-20250917_lab.xml (EX-101.LAB) — 36KB
- biaf-20250917_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 17, 2025 BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer